These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 34390295)

  • 1. Clinical outcome of dogs diagnosed with canine inflammatory mammary cancer treated with metronomic cyclophosphamide, a cyclooxygenase-2 inhibitor and toceranib phosphate.
    Alonso-Miguel D; Valdivia G; García-San José P; Alonso-Diez Á; Clares I; Portero M; Peña L; Pérez-Alenza MD
    Vet Comp Oncol; 2022 Mar; 20(1):179-188. PubMed ID: 34390295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Toceranib/Piroxicam/Cyclophosphamide Maintenance Therapy on Outcome of Dogs with Appendicular Osteosarcoma following Amputation and Carboplatin Chemotherapy: A Multi-Institutional Study.
    London CA; Gardner HL; Mathie T; Stingle N; Portela R; Pennell ML; Clifford CA; Rosenberg MP; Vail DM; Williams LE; Cronin KL; Wilson-Robles H; Borgatti A; Henry CJ; Bailey DB; Locke J; Northrup NC; Crawford-Jakubiak M; Gill VL; Klein MK; Ruslander DM; Thamm DH; Phillips B; Post G
    PLoS One; 2015; 10(4):e0124889. PubMed ID: 25923466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retrospective evaluation of canine heart base tumours treated with toceranib phosphate (Palladia): 2011-2018.
    Lew FH; McQuown B; Borrego J; Cunningham S; Burgess KE
    Vet Comp Oncol; 2019 Dec; 17(4):465-471. PubMed ID: 31069932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of toceranib, piroxicam and thalidomide with or without hypofractionated radiation therapy on clinical outcome in dogs with inflammatory mammary carcinoma.
    Rossi F; Sabattini S; Vascellari M; Marconato L
    Vet Comp Oncol; 2018 Dec; 16(4):497-504. PubMed ID: 29806156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Toceranib phosphate in the treatment of canine thyroid carcinoma: 42 cases (2009-2018).
    Sheppard-Olivares S; Bello NM; Wood E; Szivek A; Biller B; Hocker S; Wouda RM
    Vet Comp Oncol; 2020 Dec; 18(4):519-527. PubMed ID: 32012432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and immunomodulatory effects of toceranib combined with low-dose cyclophosphamide in dogs with cancer.
    Mitchell L; Thamm DH; Biller BJ
    J Vet Intern Med; 2012; 26(2):355-62. PubMed ID: 22303814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A retrospective study of proteinuria in dogs receiving toceranib phosphate.
    Piscoya SL; Hume KR; Balkman CE
    Can Vet J; 2018 Jun; 59(6):611-616. PubMed ID: 29910474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of palliative therapy, alone or in combination with toceranib phosphate, in dogs diagnosed with metastatic or recurrent beta-cell neoplasia.
    Alonso-Miguel D; García-San José P; González Sanz S; Clarés Moral I; Pérez-Alenza MD
    N Z Vet J; 2021 Jul; 69(4):234-239. PubMed ID: 33944682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retrospective evaluation of toceranib phosphate (Palladia) in cats with oral squamous cell carcinoma.
    Wiles V; Hohenhaus A; Lamb K; Zaidi B; Camps-Palau M; Leibman N
    J Feline Med Surg; 2017 Feb; 19(2):185-193. PubMed ID: 26755491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the adverse event profile and pharmacodynamics of toceranib phosphate administered to dogs with solid tumors at doses below the maximum tolerated dose.
    Bernabe LF; Portela R; Nguyen S; Kisseberth WC; Pennell M; Yancey MF; London CA
    BMC Vet Res; 2013 Sep; 9():190. PubMed ID: 24079884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toceranib phosphate (Palladia) for the treatment of canine exocrine pancreatic adenocarcinoma.
    Musser ML; Johannes CM
    BMC Vet Res; 2021 Aug; 17(1):269. PubMed ID: 34380474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retrospective evaluation of toceranib phosphate (Palladia) in the treatment of canine carcinomatosis and mesothelioma.
    Hicks KA; Leeper HJ; Curran KM
    Vet Comp Oncol; 2024 Jun; 22(2):245-254. PubMed ID: 38622074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant anthracycline-based vs metronomic chemotherapy vs no medical treatment for dogs with metastatic splenic hemangiosarcoma: A multi-institutional retrospective study of the Italian Society of Veterinary Oncology.
    Marconato L; Chalfon C; Finotello R; Polton G; Vasconi ME; Annoni M; Stefanello D; Mesto P; Capitani O; Agnoli C; Amati M; Sabattini S
    Vet Comp Oncol; 2019 Dec; 17(4):537-544. PubMed ID: 31251441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prospective, multi-centre, Veterinary Radiation Therapy Oncology Group study reveals potential efficacy of toceranib phosphate (Palladia) as a primary or adjuvant agent in the treatment of canine nasal carcinoma.
    Ehling TJ; Klein MK; Smith L; Prescott D; Haney S; Looper J; LaDue T; Brawner W; Fidel J; Shiomitsu K; Green E; Saba C; Turek M; Farrelly J
    Vet Comp Oncol; 2022 Mar; 20(1):293-303. PubMed ID: 34655275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A canine case of malignant melanoma carrying a KIT c.1725_1733del mutation treated with toceranib: a case report and in vitro analysis.
    Tani H; Miyamoto R; Noguchi S; Kurita S; Nagashima T; Michishita M; Yayoshi N; Tamura K; Bonkobara M
    BMC Vet Res; 2021 Apr; 17(1):147. PubMed ID: 33827546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision.
    London CA; Malpas PB; Wood-Follis SL; Boucher JF; Rusk AW; Rosenberg MP; Henry CJ; Mitchener KL; Klein MK; Hintermeister JG; Bergman PJ; Couto GC; Mauldin GN; Michels GM
    Clin Cancer Res; 2009 Jun; 15(11):3856-65. PubMed ID: 19470739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety evaluation of combination toceranib phosphate (Palladia®) and piroxicam in tumour-bearing dogs (excluding mast cell tumours): a phase I dose-finding study.
    Chon E; McCartan L; Kubicek LN; Vail DM
    Vet Comp Oncol; 2012 Sep; 10(3):184-93. PubMed ID: 22235941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of toceranib for treatment of apocrine gland anal sac adenocarcinoma in dogs.
    Heaton CM; Fernandes AFA; Jark PC; Pan X
    J Vet Intern Med; 2020 Mar; 34(2):873-881. PubMed ID: 31977135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Toceranib Phosphate and Carprofen on Survival and Quality of Life in Dogs with Inflammatory Mammary Carcinomas.
    Garcia-de la Virgen M; Del Portillo Miguel I; Maiques E; Pérez Roger I; Poch E; Borrego J
    Vet Sci; 2024 Sep; 11(9):. PubMed ID: 39330809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of toxicities from combined metronomic and maximal-tolerated dose chemotherapy in dogs with osteosarcoma.
    Bracha S; Walshaw R; Danton T; Holland S; Ruaux C; Obradovich J
    J Small Anim Pract; 2014 Jul; 55(7):369-74. PubMed ID: 24803081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.